Evidence map›Paper›PMID 38893435›Full record

ArticleMolecules (Basel, Switzerland)2024

An Optical Reusable 2D Radiochromic Gel-Based System for Ionising Radiation Measurements in Radiotherapy.

Marek Kozicki, Piotr Maras

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Advancements in Tissue-Equivalent Gel Dosimeters.Gels (Basel, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Marek KozickiDepartment of Mechanical Engineering, Informatics and Chemistry of Polymer Materials, Faculty of Materials Technologies and Textile Design, Lodz University of Technology, Żeromskiego 116, 90-543 Lodz, Poland.ORCID 0000-0002-8396-4344
Piotr MarasDepartment of Radiotherapy Planning, Copernicus Hospital, Pabianicka 62, 93-513 Lodz, Poland.ORCID 0000-0002-5821-4947

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This work describes the development of a reusable 2D detector based on radiochromic reaction for radiotherapy dosimetric measurements. It consists of a radiochromic gel dosimeter in a cuboidal plastic container, scanning with a flatbed scanner, and data processing using a dedicated software package. This tool is assessed using the example of the application of the coincidence test of radiation and mechanical isocenters for a medical accelerator. The following were examined: scanning repeatability and image homogeneity, the impact of image processing on data processing in coincidence tests, and irradiation conditions-monitor units per radiation beam and irradiation field are selected. Optimal conditions for carrying out the test are chosen: (i) the multi-leaf collimator gap should preferably be 5 mm for 2D star shot irradiation, (ii) it is recommended to apply ≥2500-≤5000 MU per beam to obtain a strong signal enabling easy data processing, (iii) Mean filter can be applied to the images to improve calculations. An approach to dosimeter reuse with the goal of reducing costs is presented; the number of reuses is related to the MUs per beam, which, in this study, is about 5-57 for 30,000-2500 MU per beam (four fields). The proposed reusable system was successfully applied to the coincidence tests, confirming its suitability as a new potential quality assurance tool in radiotherapy.

Indexed as

Radiation, IonizingGelsParticle AcceleratorsRadiation DosimetersRadiometryRadiotherapyRadiotherapy DosageGels2D dosimetryNBT–Pluronic F-127polyGeVero-CTquality assuranceradiotherapy dosimetry

Identifiers

PMID38893435
PMCPMC11173542

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.